TET2 and angioimmunoblastic T-cell lymphoma: Since TET2 mutations were frequently found to co-occur with a glycine to valine (G17V) inactivating mutation in Rho GTPase RhoA in 50-70% of AITL cases (12, 40, 41), several groups sought to dissect the relative contribution of RhoA-G17V mutations and TET2 loss of function to T cell lymphomagenesis.